Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018

Joseph Jy Sung, Philip Wy Chiu, Francis K L Chan, James Yw Lau, Khean-Lee Goh, Lawrence Hy Ho, Hwoon-Young Jung, Jose D Sollano, Takuji Gotoda, Nageshwar Reddy, Rajvinder Singh, Kentaro Sugano, Kai-Chun Wu, Chun-Yin Wu, David J Bjorkman, Dennis M Jensen, Ernst J Kuipers, Angel Lanas, Joseph Jy Sung, Philip Wy Chiu, Francis K L Chan, James Yw Lau, Khean-Lee Goh, Lawrence Hy Ho, Hwoon-Young Jung, Jose D Sollano, Takuji Gotoda, Nageshwar Reddy, Rajvinder Singh, Kentaro Sugano, Kai-Chun Wu, Chun-Yin Wu, David J Bjorkman, Dennis M Jensen, Ernst J Kuipers, Angel Lanas

Abstract

Non-variceal upper gastrointestinal bleeding remains an important emergency condition, leading to significant morbidity and mortality. As endoscopic therapy is the 'gold standard' of management, treatment of these patients can be considered in three stages: pre-endoscopic treatment, endoscopic haemostasis and post-endoscopic management. Since publication of the Asia-Pacific consensus on non-variceal upper gastrointestinal bleeding (NVUGIB) 7 years ago, there have been significant advancements in the clinical management of patients in all three stages. These include pre-endoscopy risk stratification scores, blood and platelet transfusion, use of proton pump inhibitors; during endoscopy new haemostasis techniques (haemostatic powder spray and over-the-scope clips); and post-endoscopy management by second-look endoscopy and medication strategies. Emerging techniques, including capsule endoscopy and Doppler endoscopic probe in assessing adequacy of endoscopic therapy, and the pre-emptive use of angiographic embolisation, are attracting new attention. An emerging problem is the increasing use of dual antiplatelet agents and direct oral anticoagulants in patients with cardiac and cerebrovascular diseases. Guidelines on the discontinuation and then resumption of these agents in patients presenting with NVUGIB are very much needed. The Asia-Pacific Working Group examined recent evidence and recommends practical management guidelines in this updated consensus statement.

Keywords: endoscopy; gastrointestinal bleeding.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Sung JJ, Chan FK, Chen M, et al. . Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding. Gut 2011;60:1170–7. 10.1136/gut.2010.230292
    1. Stanley AJ, Laine L, Dalton HR, et al. . Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ 2017;356:i6432 10.1136/bmj.i6432
    1. Park SM, Yeum SC, Kim B-W, et al. . Comparison of AIMS65 score and other scoring systems for predicting clinical outcomes in Koreans with nonvariceal upper gastrointestinal bleeding. Gut Liver 2016;10:526–31. 10.5009/gnl15153
    1. Yang HM, Jeon SW, Jung JT, et al. . Comparison of scoring systems for nonvariceal upper gastrointestinal bleeding: a multicenter prospective cohort study. J Gastroenterol Hepatol 2016;31:119–25. 10.1111/jgh.13057
    1. Martínez-Cara JG, Jiménez-Rosales R, Úbeda-Muñoz M, et al. . Comparison of AIMS65, Glasgow-Blatchford score, and Rockall score in a European series of patients with upper gastrointestinal bleeding: performance when predicting in-hospital and delayed mortality. United European Gastroenterol J 2016;4:371–9. 10.1177/2050640615604779
    1. Laursen SB, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012;10:1130–5. 10.1016/j.cgh.2012.06.022
    1. Robertson M, Majumdar A, Boyapati R, et al. . Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. Gastrointest Endosc 2016;83:1151–60. 10.1016/j.gie.2015.10.021
    1. Bryant RV, Kuo P, Williamson K, et al. . Performance of the Glasgow-Blatchford score in predicting clinical outcomes and intervention in hospitalized patients with upper GI bleeding. Gastrointest Endosc 2013;78:576–83. 10.1016/j.gie.2013.05.003
    1. Thanapirom K, Ridtitid W, Rerknimitr R, et al. . Prospective comparison of three risk scoring systems in non-variceal and variceal upper gastrointestinal bleeding. J Gastroenterol Hepatol 2016;31:761–7. 10.1111/jgh.13222
    1. Mokhtare M, Bozorgi V, Agah S, et al. . Comparison of Glasgow-Blatchford score and full Rockall score systems to predict clinical outcomes in patients with upper gastrointestinal bleeding. Clin Exp Gastroenterol 2016;9:337–43. 10.2147/CEG.S114860
    1. Ramaekers R, Mukarram M, Smith CA, et al. . The predictive value of preendoscopic risk scores to predict adverse outcomes in emergency department patients with upper gastrointestinal bleeding: a systematic review. Acad Emerg Med 2016;23:1218–27. 10.1111/acem.13101
    1. Laursen SB, Dalton HR, Murray IA, et al. . Performance of new thresholds of the Glasgow Blatchford score in managing patients with upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2015;13:115–21. 10.1016/j.cgh.2014.07.023
    1. Sung JJ, Tsoi KK, Ma TK, et al. . Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010;105:84–9. 10.1038/ajg.2009.507
    1. Blair SD, Janvrin SB, McCollum CN, et al. . Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783–5. 10.1002/bjs.1800731007
    1. Villanueva C, Colomo A, Bosch A, et al. . Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med Overseas Ed 2013;368:11–21. 10.1056/NEJMoa1211801
    1. Jairath V, Kahan BC, Gray A, et al. . Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER): a pragmatic, open-label, cluster randomised feasibility trial. Lancet 2015;386:137–44. 10.1016/S0140-6736(14)61999-1
    1. Lee JM, Chun HJ, Lee JS, et al. . Sa1888 target level for hemoglobin correction in patients with acute non-variceal upper gastrointestinal bleeding. Gastroenterology 2014;146:S-321 10.1016/S0016-5085(14)61157-4
    1. Odutayo A, Desborough MJ, Trivella M, et al. . Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials. Lancet Gastroenterol Hepatol 2017;2:354–60. 10.1016/S2468-1253(17)30054-7
    1. Fabricius R, Svenningsen P, Hillingsø J, et al. . Effect of transfusion strategy in acute non-variceal upper gastrointestinal bleeding: a nationwide study of 5861 hospital admissions in Denmark. World J Surg 2016;40:1129–36. 10.1007/s00268-015-3370-4
    1. Restellini S, Kherad O, Jairath V, et al. . Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding. Aliment Pharmacol Ther 2013;37:316–22. 10.1111/apt.12170
    1. Subramaniam K, Spilsbury K, Ayonrinde OT, et al. . Red blood cell transfusion is associated with further bleeding and fresh-frozen plasma with mortality in nonvariceal upper gastrointestinal bleeding. Transfusion 2016;56:816–26. 10.1111/trf.13446
    1. Zakko L, Rustagi T, Douglas M, et al. . No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents. Clin Gastroenterol Hepatol 2017;15:46–52. 10.1016/j.cgh.2016.07.017
    1. Victor N, Umakanthan J, Gandhi A, et al. . 419: role of platelet transfusion in gastrointestinal bleeding in patients on antiplatelet therapy. Crit Care Med 2014;42:A1461 10.1097/01.ccm.0000457916.80100.82
    1. Tsoi KK, Ma TK, Sung JJ. Endoscopy for upper gastrointestinal bleeding: how urgent is it? Nat Rev Gastroenterol Hepatol 2009;6:463–9. 10.1038/nrgastro.2009.108
    1. Kumar NL, Cohen AJ, Nayor J, et al. . Timing of upper endoscopy influences outcomes in patients with acute nonvariceal upper GI bleeding. Gastrointest Endosc 2017;85:945–52. 10.1016/j.gie.2016.09.029
    1. Laursen SB, Leontiadis GI, Stanley AJ, et al. . Relationship between timing of endoscopy and mortality in patients with peptic ulcer bleeding: a nationwide cohort study. Gastrointest Endosc 2017;85:936–44. 10.1016/j.gie.2016.08.049
    1. Jairath V, Kahan BC, Logan RF, et al. . Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. Endoscopy 2012;44:723–30. 10.1055/s-0032-1309736
    1. Lim LG, Ho KY, Chan YH, et al. . Urgent endoscopy is associated with lower mortality in high-risk but not low-risk nonvariceal upper gastrointestinal bleeding. Endoscopy 2011;43:300–6. 10.1055/s-0030-1256110
    1. Wong JC, Lau JY, Tang RS, et al. . 785 urgent versus early endoscopy for upper gastrointestinal bleeding with Glasgow-Blatchford score ≥12. Gastroenterology 2015;148:S-154 10.1016/S0016-5085(15)30520-5
    1. Sung JJ, Luo D, Wu JC, et al. . Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011;43:291–5. 10.1055/s-0030-1256311
    1. Thayalasekaran S, Dixon S, Mundre P, et al. . Mo1118 Hemospray use in the management of upper gastrointestinal hemorrhage: a 2-year experience across two teaching hospitals in the North and South of England. Gut 2017;66:A232 10.1016/j.gie.2017.03.1010
    1. Haddara S, Jacques J, Lecleire S, et al. . A novel hemostatic powder for upper gastrointestinal bleeding: a multicenter study (the “GRAPHE” registry). Endoscopy 2016;48:1084–95. 10.1055/s-0042-116148
    1. Sinha R, Lockman KA, Church NI, et al. . The use of hemostatic spray as an adjunct to conventional hemostatic measures in high-risk nonvariceal upper GI bleeding (with video). Gastrointest Endosc 2016;84:900–6. 10.1016/j.gie.2016.04.016
    1. Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015;47:167–71. 10.1055/s-0034-1378098
    1. Masci E, Arena M, Morandi E, et al. . Upper gastrointestinal active bleeding ulcers: review of literature on the results of endoscopic techniques and our experience with Hemospray. Scand J Gastroenterol 2014;49:1–6. 10.3109/00365521.2014.946080
    1. Yau AH, Ou G, Galorport C, et al. . Safety and efficacy of Hemospray® in upper gastrointestinal bleeding. Can J Gastroenterol Hepatol 2014;28:72–6.
    1. Smith LA, Stanley AJ, Bergman JJ, et al. . Hemospray application in nonvariceal upper gastrointestinal bleeding: results of the Survey to Evaluate the Application of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014;48:e89–92. 10.1097/MCG.0000000000000054
    1. Holster IL, Kuipers EJ, Tjwa ET. Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy 2013;45:63–6. 10.1055/s-0032-1325793
    1. Chan SM, Chiu PW, Teoh AY, et al. . Use of the over-the-scope clip for treatment of refractory upper gastrointestinal bleeding: a case series. Endoscopy 2014;46:428–31. 10.1055/s-0034-1364932
    1. Wedi E, Gonzalez S, Menke D, et al. . One hundred and one over-the-scope-clip applications for severe gastrointestinal bleeding, leaks and fistulas. World J Gastroenterol 2016;22:1844–53. 10.3748/wjg.v22.i5.1844
    1. Manta R, Galloro G, Mangiavillano B, et al. . Over-the-scope clip (OTSC) represents an effective endoscopic treatment for acute GI bleeding after failure of conventional techniques. Surg Endosc 2013;27:3162–4. 10.1007/s00464-013-2871-1
    1. Kirschniak A, Subotova N, Zieker D, et al. . The over-the-scope clip (OTSC) for the treatment of gastrointestinal bleeding, perforations, and fistulas. Surg Endosc 2011;25:2901–5. 10.1007/s00464-011-1640-2
    1. Schmidt A, Goelder S, Messmann H, et al. . 62 over-the-scope-clips versus standard endoscopic therapy in patients with recurrent peptic ulcer bleeding and a prospective randomized, multicenter trial (Sting). Gastrointest Endosc 2017;85:AB50 10.1016/j.gie.2017.03.043
    1. Libânio D, Costa MN, Pimentel-Nunes P, et al. . Risk factors for bleeding after gastric endoscopic submucosal dissection: a systematic review and meta-analysis. Gastrointest Endosc 2016;84:572–86. 10.1016/j.gie.2016.06.033
    1. Yang Z, Wu Q, Liu Z, et al. . Proton pump inhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials. Digestion 2011;84:315–20. 10.1159/000331138
    1. Tomita T, Kim Y, Yamasaki T, et al. . Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection. J Gastroenterol Hepatol 2012;27:1441–6. 10.1111/j.1440-1746.2012.07144.x
    1. Kim EH, Park SW, Nam E, et al. . Role of second-look endoscopy and prophylactic hemostasis after gastric endoscopic submucosal dissection: a systematic review and meta-analysis. J Gastroenterol Hepatol 2017;32:756–68. 10.1111/jgh.13623
    1. Khuroo MS, Yattoo GN, Javid G, et al. . A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med Overseas Ed 1997;336:1054–8. 10.1056/NEJM199704103361503
    1. Javid G, Masoodi I, Zargar SA, et al. . Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001;111:280–4. 10.1016/S0002-9343(01)00812-9
    1. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. . Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003;17:211–6. 10.1046/j.1365-2036.2003.01416.x
    1. Sung JJ, Suen BY, Wu JC, et al. . Effects of intravenous and oral esomeprazole in the prevention of recurrent bleeding from peptic ulcers after endoscopic therapy. Am J Gastroenterol 2014;109:1005–10. 10.1038/ajg.2014.105
    1. Yen HH, Yang CW, Su WW, et al. . Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. BMC Gastroenterol 2012;12:66 10.1186/1471-230X-12-66
    1. Kim HK, Kim JS, Kim TH, et al. . Effect of high-dose oral rabeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Gastroenterol Res Pract 2012;2012:1–8. 10.1155/2012/317125
    1. Fernando H, Bassler N, Habersberger J, et al. . Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011;9:1582–9. 10.1111/j.1538-7836.2011.04414.x
    1. Furuta T, Sugimoto M, Kodaira C, et al. . Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017;43:333–42. 10.1007/s11239-016-1460-2
    1. Ohbuchi M, Noguchi K, Kawamura A, et al. . Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4. Xenobiotica 2012;42:633–40. 10.3109/00498254.2011.653655
    1. Zvyaga T, Chang SY, Chen C, et al. . Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 2012;40:1698–711. 10.1124/dmd.112.045575
    1. Ogilvie BW, Yerino P, Kazmi F, et al. . The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011;39:2020–33. 10.1124/dmd.111.041293
    1. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010;70:383–92. 10.1111/j.1365-2125.2010.03717.x
    1. Zou JJ, Chen SL, Tan J, et al. . Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor. PLoS One 2014;9:e84985 10.1371/journal.pone.0084985
    1. Ortolani P, Marino M, Marzocchi A, et al. . One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. J Cardiovasc Med 2012;13:783–9. 10.2459/JCM.0b013e3283416b6b
    1. Muñoz-Torrero JF, Escudero D, Suárez C, et al. . Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry. J Cardiovasc Pharmacol 2011;57:13–19. 10.1097/FJC.0b013e3181fc65e5
    1. Chitose T, Hokimoto S, Oshima S, et al. . Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012;76:71–8. 10.1253/circj.CJ-11-0699
    1. Valkhoff VE, ’t Jong GW, Van Soest EM, et al. . Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011;33:77–88. 10.1111/j.1365-2036.2010.04485.x
    1. Juurlink DN, Gomes T, Mamdani MM, et al. . The safety of proton pump inhibitors and clopidogrel in patients after stroke. Stroke 2011;42:128–32. 10.1161/STROKEAHA.110.596643
    1. Bhatt DL, Cryer BL, Contant CF, et al. . Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med Overseas Ed 2010;363:1909–17. 10.1056/NEJMoa1007964
    1. Vaduganathan M, Cannon CP, Cryer BL, et al. . Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med 2016;129:1002–5. 10.1016/j.amjmed.2016.03.042
    1. Ryu HY, Kim JW, Kim HS, et al. . Second-look endoscopy is not associated with better clinical outcomes after gastric endoscopic submucosal dissection: a prospective, randomized, clinical trial analyzed on an as-treated basis. Gastrointest Endosc 2013;78:285–94. 10.1016/j.gie.2013.02.008
    1. Jensen DM, Ohning GV, Kovacs TO, et al. . Doppler endoscopic probe as a guide to risk stratification and definitive hemostasis of peptic ulcer bleeding. Gastrointest Endosc 2016;83:129–36. 10.1016/j.gie.2015.07.012
    1. Kim JS, Chung MW, Chung CY, et al. . The need for second-look endoscopy to prevent delayed bleeding after endoscopic submucosal dissection for gastric neoplasms: a prospective randomized trial. Gut Liver 2014;8:480–6. 10.5009/gnl13226
    1. Mochizuki S, Uedo N, Oda I, et al. . Scheduled second-look endoscopy is not recommended after endoscopic submucosal dissection for gastric neoplasms (the SAFE trial): a multicentre prospective randomised controlled non-inferiority trial. Gut 2015;64:397–405. 10.1136/gutjnl-2014-307552
    1. Cea Soriano L, Bueno H, Lanas A, et al. . Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost 2013;110:1298–304. 10.1160/TH13-04-0326
    1. Sung JJ, Lau JY, Ching JY, et al. . Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1–9. 10.7326/0003-4819-152-1-201001050-00179
    1. Derogar M, Sandblom G, Lundell L, et al. . Discontinuation of low-dose aspirin therapy after peptic ulcer bleeding increases risk of death and acute cardiovascular events. Clin Gastroenterol Hepatol 2013;11:38–42. 10.1016/j.cgh.2012.08.034
    1. Liu CP, Chen WC, Lai KH, et al. . Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. Am J Gastroenterol 2012;107:1022–9. 10.1038/ajg.2012.87
    1. Abraham NS, Hartman C, Richardson P, et al. . Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation 2013;128:1869–77. 10.1161/CIRCULATIONAHA.113.004747
    1. Eisenberg MJ, Richard PR, Libersan D, et al. . Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634–42. 10.1161/CIRCULATIONAHA.108.813667
    1. Acosta RD, Abraham NS, Chandrasekhara V, et al. . The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83:3–16. 10.1016/j.gie.2015.09.035
    1. Shingina A, Barkun AN, Razzaghi A, et al. . Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 2011;33:1010–8. 10.1111/j.1365-2036.2011.04618.x
    1. Halvorsen S, Storey RF, Rocca B, et al. . Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2017;38:1455–62. 10.1093/eurheartj/ehw454
    1. Pollack CV, Reilly PA, van Ryn J, et al. . Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med Overseas Ed 2017;377:431–41. 10.1056/NEJMoa1707278
    1. Gage BF, Waterman AD, Shannon W, et al. . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
    1. Lip GY, Frison L, Halperin JL, et al. . Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173–80. 10.1016/j.jacc.2010.09.024
    1. Zulkifly H, Lip GYH, Lane DA. Bleeding risk scores in atrial fibrillation and venous thromboembolism. Am J Cardiol 2017;120:1139–45. 10.1016/j.amjcard.2017.06.058
    1. Qureshi WT, Nasir U. Restarting oral anticoagulation among patients with atrial fibrillation with gastrointestinal bleeding was associated with lower risk of all-cause mortality and thromboembolism. Evid Based Med 2016;21:152 10.1136/ebmed-2016-110444
    1. Scott MJ, Veitch A, Thachil J. Reintroduction of anti-thrombotic therapy after a gastrointestinal haemorrhage: if and when? Br J Haematol 2017;177:185–97. 10.1111/bjh.14599
    1. Hernandez I, Zhang Y, Brooks MM, et al. . Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke 2017;48:159–66. 10.1161/STROKEAHA.116.015150
    1. Gralnek IM, Ching JY, Maza I, et al. . Capsule endoscopy in acute upper gastrointestinal hemorrhage: a prospective cohort study. Endoscopy 2013;45:12–19. 10.1055/s-0032-1325933
    1. Sung JJ, Tang RS, Ching JY, et al. . Use of capsule endoscopy in the emergency department as a triage of patients with GI bleeding. Gastrointest Endosc 2016;84:907–13. 10.1016/j.gie.2016.04.043
    1. Gutkin E, Shalomov A, Hussain SA, et al. . Pillcam ESO is more accurate than clinical scoring systems in risk stratifying emergency room patients with acute upper gastrointestinal bleeding. Therap Adv Gastroenterol 2013;6:193–8. 10.1177/1756283X13481020
    1. Meltzer AC, Pinchbeck C, Burnett S, et al. . Emergency physicians accurately interpret video capsule endoscopy findings in suspected upper gastrointestinal hemorrhage: a video survey. Acad Emerg Med 2013;20:711–5. 10.1111/acem.12165
    1. Meltzer AC, Ward MJ, Gralnek IM, et al. . The cost-effectiveness analysis of video capsule endoscopy compared to other strategies to manage acute upper gastrointestinal hemorrhage in the ED. Am J Emerg Med 2014;32:823–32. 10.1016/j.ajem.2013.11.012
    1. Chandran S, Testro A, Urquhart P, et al. . Risk stratification of upper GI bleeding with an esophageal capsule. Gastrointest Endosc 2013;77:891–8. 10.1016/j.gie.2013.01.003
    1. Daneshmend TK, Hawkey CJ, Langman MJ, et al. . Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992;304:143–7. 10.1136/bmj.304.6820.143
    1. Hawkey GM, Cole AT, McIntyre AS, et al. . Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001;49:372–9. 10.1136/gut.49.3.372
    1. Hulagu S, Demirturk L, Gul S, et al. . The effect of omprazole or ranitidine intravenous on upper gastrointestinal bleeding. Endoskop J 1995;2:35–43.
    1. Naumovski-Mihalic S, Katicic M, Colic-Cvrlje V, et al. . Intravenous proton pump inhibitor in ulcer bleeding in patients admitted to intensive care unit. Gastroenterology 2005;128:A641.
    1. Wallner G, Ciechanski A, Wesolowski M, et al. . Treatment of acute upper gastrointestinal bleeding with intravenous omeprazole or ranitidine. Eur J Med Res 1996;8:235–43.
    1. Lau JY, Leung WK, Wu JCY, et al. . Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med Overseas Ed 2007;356:1631–40. 10.1056/NEJMoa065703
    1. Sreedharan A, Martin J, Leontiadis GI, et al. . Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010;304:CD005415 10.1002/14651858.CD005415.pub3
    1. Ripoll C, Bañares R, Beceiro I, et al. . Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol 2004;15:447–50. 10.1097/01.RVI.0000126813.89981.B6
    1. Wong TC, Wong KT, Chiu PW, et al. . A comparison of angiographic embolization with surgery after failed endoscopic hemostasis to bleeding peptic ulcers. Gastrointest Endosc 2011;73:900–8. 10.1016/j.gie.2010.11.024
    1. Laursen SB, Hansen JM, Andersen PE, et al. . Supplementary arteriel embolization an option in high-risk ulcer bleeding--a randomized study. Scand J Gastroenterol 2014;49:75–83. 10.3109/00365521.2013.854829
    1. Lau JY, Wong K, Chiu PW, et al. . Early angiographic embolization after endoscopic hemostasis to high risk bleeding peptic ulcers improves outcomes. Gastrointest Endosc 2014;79:AB113 10.1016/S0016-5085(14)60151-7
    1. Villanueva C, Balanzó J, Torras X, et al. . Value of second-look endoscopy after injection therapy for bleeding peptic ulcer: a prospective and randomized trial. Gastrointest Endosc 1994;40:34–9. 10.1016/S0016-5107(94)70006-0
    1. Messmann H, Schaller P, Andus T, et al. . Effect of programmed endoscopic follow-up examinations on the rebleeding rate of gastric or duodenal peptic ulcers treated by injection therapy: a prospective, randomized controlled trial. Endoscopy 1998;30:583–9. 10.1055/s-2007-1001360
    1. Saeed ZA, Cole RA, Ramirez FC, et al. . Endoscopic retreatment after successful initial hemostasis prevents ulcer rebleeding: a prospective randomized trial. Endoscopy 1996;28:288–94. 10.1055/s-2007-1005455
    1. Chiu PW, Lam CY, Lee SW, et al. . Effect of scheduled second therapeutic endoscopy on peptic ulcer rebleeding: a prospective randomised trial. Gut 2003;52:1403–7. 10.1136/gut.52.10.1403
    1. El Ouali S, Barkun AN, Wyse J, et al. . Is routine second-look endoscopy effective after endoscopic hemostasis in acute peptic ulcer bleeding? A meta-analysis. Gastrointest Endosc 2012;76:283–92. 10.1016/j.gie.2012.04.441
    1. Chiu PW, Joeng HK, Choi CL, et al. . High-dose omeprazole infusion compared with scheduled second-look endoscopy for prevention of peptic ulcer rebleeding: a randomized controlled trial. Endoscopy 2016;48:717–22. 10.1055/s-0042-107590
    1. Saeed ZA, Ramirez FC, Hepps KS, et al. . Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc 1995;41:561–5. 10.1016/S0016-5107(95)70191-5
    1. Kim SB, Lee SH, Kim KO, et al. . Risk factors associated with rebleeding in patients with high risk peptic ulcer bleeding: focusing on the role of second look endoscopy. Dig Dis Sci 2016;61:517–22. 10.1007/s10620-015-3846-y
    1. Cheng HC, Wu CT, Chen WY, et al. . Risk factors determining the need for second-look endoscopy for peptic ulcer bleeding after endoscopic hemostasis and proton pump inhibitor infusion. Endosc Int Open 2016;4:E255–62. 10.1055/s-0041-111499
    1. Jensen DM, Kovacs TOG, Ohning GV, et al. . Doppler endoscopic probe monitoring of blood flow improves risk stratification and outcomes of patients with severe nonvariceal upper gastrointestinal hemorrhage. Gastroenterology 2017;152:1310–8. 10.1053/j.gastro.2017.01.042

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere